NCT05196087Recruiting
Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
Patients who have undergone curative treatment may be at risk of relapse. This study will collect, annotate, and sequence biospecimens (blood, stool, and tissue) from patients across different tumor types to detect molecular residual disease (MRD) before metastases become radiographically or clinically detectable. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 13 Dec 2021
- Start date
- 20 Jul 2022
- Primary completion date
- Jun 2028
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Neuroendocrine tumours, Melanoma
- NCT number
- NCT05196087
What you commit to
- Study type: Observational
- Planned participants: 800
- From 20 Jul 2022 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients with histological confirmation of a solid tumor.
- Patients must have early stage or locally advanced disease that is planned for or have undergone curative treatment.
- Patient must be ≥ 18 years old.
- All patients must have signed and dated an informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Cancer Centre Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.